Sequential treatment of a resistant chronic lymphocytic leukemia patient with Bryostatin 1 followed by 2-chlorodeoxyadenosine: Case report

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1328-1332

  Ahmad, Ishtiaq ^a   Al Katib, Ayad M ^a   Beck, Frances W J ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CLADRIBINE;

AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; ENZYME ACTIVITY; GROWTH INHIBITION; HAIRY CELL LEUKEMIA; HUMAN; LYMPHOCYTE COUNT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TUMOR GROWTH;

5'-NUCLEOTIDASE; AGED; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CLADRIBINE; CLINICAL TRIALS, PHASE I; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAXBETA2; LACTONES; LECTINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTES; MACROLIDES; MALE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0034088936     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Drexler, H. G., Gignac, S. M., Jones, R. A., Scott, C. S., Pettit, G. R., and Hoffbrand, A. V. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood, 74: 1747-1757, 1989.
2. Al-Katib, A. M., Mohammad, R. M., Dan, M., Hussein, M. E., Akhtar, A., Pettit, G. R., and Sensenbrenner, L. L. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol., 21: 61-65, 1993.
3. Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., and Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
4. Lauria, F., Rondelli, D., Zinzani, P. L., Bocchia, M., Marotta, G., Salvucci, M., Raspadori, D., Ventura, M. A., Birtoto, M. A., Forconi, F., and Tura, S. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia (Baltimore), 11: 629-632, 1997.
5. Saven, A., and Piro, L. D. Newer purine analogue for the treatment of hairy cell leukemia. N. Engl. J. Med., 330: 691-697, 1994.
6. Mohammad, R. M., Katato, K., Almatchy, V. P., Wall, N., Liu, K., Schulz, C. P., Mantsch, H. H., Varterasian, M., and Al-Katib, A. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin. Cancer Res., 4: 445-453, 1998.
7. Mohammad, R. M., Beck, F. W. J., Katato, K., Hamdy, N., Wall, N., and Al-Katib, A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/ Bcl-2. Biol. Chem., 379: 1253-1261, 1998.
8. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S., and Rai, K. R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87: 4990-4997, 1996.
9. Kraft, A. S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells. Proc. Natl. Acad. Sci. USA, 83: 1334-1338, 1986.
10. Kraft, A. S., Reeves, J. A., and Ashendel, C. L. Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells. J. Biol. Chem., 263: 8437-8442, 1988.
11. Varterasian, M. L., Mohammad, R. M., Eilender, D. S., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Pluda, J. M., Dan, M. D., Pettit, G. R., Chen, B. D. M., and Al-Katib, A. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 16: 56-62, 1998.
12. Carson, D. A., Wasson, D. B., Taetle, R., and Yu, A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood, 62: 737-743, 1983.
13. Beck, F. W. J., Al-Katib, A. M., Ahmad, I., and Mohammad, R. M. Bryostatin I enhances 2-chlorodeoxyadenosine (2CdA) chemotherapeutic activity in human chronic lymphocytic leukemia cells by increasing 2CdA influx and deoxycytidine kinase (dCK) activity. Blood, 94: 295b, 1999.
14. Kawasaki, H., Carrera, C. J., Piro, D. L., Saven, A., Kipps, T. J., and Carson, D. A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81: 597-601, 1993.
15. Hentosh. P., Koob, R., and Blakley, R. L. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerase α and β. J. Biol. Chem., 265: 4033-4040, 1990.
16. Parker, W. B., Bapt, A. R., Shen, J. X., Townsend, A. J., and Cheng, Y. C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primers, and ribonucleotide reductase. Mol. Pharmacol., 34: 485-491, 1988.
17. Leoni, L. M., Chao, Q., Cottam, H. B., Genini, D., Rosenbach, M., Carrera, C. J., Budiharjo, I., Wang, X., and Carson, D. A. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc. Natl. Acad. Sci. USA, 95: 9567-9571, 1998.